NPSR1

NPSR1 is a G protein-coupled receptor that transduces neuropeptide S (NPS) signaling to regulate arousal, anxiety, neuroendocrine stress responses, and immune-inflammatory processes. Existing as two major isoforms (NPSR1-A and NPSR1-B) with distinct C-termini but shared signaling capacity, ligand-activated NPSR1 couples to both Gαs (cAMP/PKA) and Gαq (IP3/calcium) pathways—mobilizing ER calcium via IP3 and ryanodine receptors followed by store-operated calcium entry—and activates MAPK/ERK and MAPK/JNK cascades, driving transcriptional programs encompassing immediate-early genes, circadian clock regulators including a feedback loop with RORA, and pro-inflammatory cytokines such as IL-6, CXCL8, and PTGS2 (PMID:21707994, PMID:25714705, PMID:40752839, PMID:23565190). NPSR1 is required in vivo for NPS-induced hyperlocomotion, anxiolysis, and HPA axis activation (PMID:20171785), and promotes CD4+ T cell effector function and intestinal inflammation in colitis models (PMID:39332092).

1. 2005 Medium

   Establishing that NPSR1 isoforms are functional GPCRs requiring full seven-transmembrane topology for plasma membrane targeting resolved whether the multiple splice variants all signal at the cell surface, and linked NPSR1-A activation to growth inhibition.

   Evidence Immunohistochemistry, in situ hybridization, and cell-based NPS stimulation assays in heterologous cells

   PMID:15947423

   Open questions at the time

   • Growth inhibition observed in a single cell model; tissue-specific relevance unclear
   • Mechanism of growth inhibition not dissected
2. 2006 Medium

   Identification of NPS-NPSR1 downstream transcriptional targets (MMP10, INHBA, IL8, EPHA2, JUN/FOS) and enriched pathways (cell proliferation, immune response, morphogenesis) established that NPSR1 is not merely a signaling relay but drives broad transcriptional reprogramming.

   Evidence Microarray, qRT-PCR, and immunoassay after NPS stimulation of NPSR1-expressing cells

   PMID:16926187

   Open questions at the time

   • Target gene regulation not validated by loss-of-function approaches
   • Physiological cell type context not tested
3. 2006 Medium

   Demonstration that NPSR1-deficient mice have attenuated thromboxane-induced bronchoconstriction provided the first in vivo evidence that NPSR1 modulates airway physiology through neural pathways.

   Evidence NPSR1-knockout mouse, airway resistance measurements with thromboxane and methacholine challenge

   PMID:16829631

   Open questions at the time

   • Neurally mediated mechanism inferred but not directly demonstrated
   • Methacholine response unaffected, limiting generality of airway role
4. 2008 Medium

   Finding that LPS upregulates NPSR1 expression in monocytes connected NPSR1 to innate immune activation, suggesting its expression is dynamically regulated during inflammation.

   Evidence LPS stimulation of monocytes with FACS and qRT-PCR readouts

   PMID:18285428

   Open questions at the time

   • Transcription factor mediating LPS-induced NPSR1 upregulation not identified
   • Functional consequence of upregulation on monocyte biology not tested
5. 2010 High

   Definitive demonstration that NPSR1 is required for NPS-induced hyperlocomotion, anxiolysis, and corticosterone release resolved whether alternative receptors could mediate NPS effects in the CNS.

   Evidence NPSR1-knockout mice with ICV NPS administration, open-field, forced swim, Morris water maze, and plasma corticosterone measurement

   PMID:20171785

   Open questions at the time

   • Brain region-specific requirement for NPSR1 not mapped
   • Downstream neural circuit mechanisms not elucidated
6. 2011 High

   Parallel signaling analysis of NPSR1-A and NPSR1-B revealed shared coupling to cAMP/PKA, MAPK/JNK, and MAPK/ERK pathways but quantitative differences in potency, establishing that isoform-specific C-terminal sequences modulate signaling amplitude rather than pathway selectivity.

   Evidence HEK-293 overexpression, NPS dose-response, cAMP/Ca²⁺ assays, pathway reporters, Affymetrix expression arrays

   PMID:21707994

   Open questions at the time

   • Structural basis for isoform-specific signaling amplitude differences unknown
   • Isoform-specific roles in native tissues not determined
7. 2011 High

   Functional characterization of multiple NPSR1 coding and promoter SNPs showed that natural genetic variation quantitatively tunes receptor signaling output, with Cys197Phe acting as a loss-of-function variant, providing a mechanistic basis for NPSR1 disease associations.

   Evidence Luciferase reporters, cAMP assays, genome-wide transcriptional profiling of defined NPSR1 variant alleles

   PMID:22216302

   Open questions at the time

   • Crystal structure not available to explain variant effects on receptor conformation
   • Population-level phenotypic consequences of individual variants not established
8. 2013 Medium

   Discovery that NPSR1 activation induces RORA and circadian clock gene expression while RORA suppresses the NPSR1 promoter uncovered a reciprocal regulatory loop linking NPSR1 to circadian biology.

   Evidence Cell-based NPS stimulation, RORA overexpression with NPSR1 promoter-luciferase, Npsr1-KO mouse lung expression analysis

   PMID:23565190

   Open questions at the time

   • Direct RORA binding to NPSR1 promoter not demonstrated by ChIP
   • Circadian behavioral consequences of disrupted loop not tested
9. 2015 Medium

   Calcium imaging in primary hippocampal neurons delineated the full calcium signaling cascade downstream of NPSR1: IP3 receptor and ryanodine receptor-mediated ER release followed by store-operated calcium entry, providing the first neuronal characterization of NPSR1 calcium coupling.

   Evidence Single-cell calcium imaging in NPSR1-expressing hippocampal cultures with pharmacological pathway dissection

   PMID:25714705

   Open questions at the time

   • NPSR1 endogenous expression level in hippocampal neurons not established
   • Downstream consequences of calcium mobilization for neuronal function not explored
10. 2017 Medium

    Showing that natural NPS ligand variants (Val6 vs Leu6) differentially activate NPSR1 variant receptors established that signal output is determined by the combinatorial pairing of ligand and receptor polymorphisms.

    Evidence Transfected cells with NPS/NPSR1 variant combinations, cAMP/PKA reporter and gene expression readouts

    PMID:28463995

    Open questions at the time

    • In vivo relevance of NPS variant-receptor variant interactions not tested
    • Binding affinity differences between ligand variants not directly measured
11. 2024 Medium

    Demonstration that NPSR1 promotes CD4+ T cell effector function, differentiation, and Th1 chemotaxis in colitis models extended NPSR1 biology from innate immunity and neuronal signaling to adaptive immune regulation in intestinal inflammation.

    Evidence IBD patient biopsies, DSS-induced colitis model, NPSR1 knockdown with flow cytometry, EdU proliferation, apoptosis, and migration assays

    PMID:39332092

    Open questions at the time

    • T cell-intrinsic versus indirect effects not fully separated
    • NPS ligand source in intestinal microenvironment not identified
12. 2025 Medium

    Pharmacological NPSR1 antagonism reduced peritoneal TNF-α in vivo and blocked pro-inflammatory cytokine induction in vitro, providing proof-of-concept that NPSR1 is a druggable anti-inflammatory target.

    Evidence Cell-based calcium/cAMP assays, NPSR1 antagonist in human fibroblasts and murine zymosan peritonitis model

    PMID:40752839

    Open questions at the time

    • Antagonist selectivity profile not fully characterized
    • Chronic disease model efficacy not tested

• Key unresolved questions include the structural basis of NPSR1 isoform-specific signaling, the identity of endogenous NPS sources in peripheral tissues, the cell-type-specific transcriptional programs driven by NPSR1 in native immune and neuronal contexts, and whether NPSR1 antagonism has therapeutic utility in chronic inflammatory or neuropsychiatric disease.
• No high-resolution NPSR1 structure available
• Endogenous NPS sources in peripheral inflammation unknown
• Cell-type-resolved NPSR1 signaling in vivo not mapped